SCHEMBL5445874

SCHEMBL5445874

Cc1c(CC(=O)O)c2cc(O)c(F)cc2n1C(=O)c1ccc(OC(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.58
AKR1C2 P52895 7/20 0.58
LMNA P02545 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
HIF1A Q16665 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
PTGS1 P23219 3/20 0.53
PTGS2 P35354 3/20 0.53
ABCB1 P08183 2/20 0.53
AKR1C4 P17516 2/20 0.53
AKR1C1 Q04828 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
PTGES O14684 1/20 0.53
ABCC3 O15438 1/20 0.53
ABCC4 O15439 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5554258 0.91 PTGS2 (0.54) AKR1C3AKR1C2LMNACYP1A2CYP2D6
SCHEMBL5559115 0.90 PTGS2 (0.49) AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL5554194 0.89 PTGS2 (0.55) AKR1C3AKR1C2PTGS1PTGS2MAPT
SCHEMBL5442566 0.89 PTGS1 (0.59) AKR1C3AKR1C2LMNACYP1A2CYP2D6
SCHEMBL5442372 0.89 AKR1C3 (0.72) AKR1C3AKR1C2LMNACYP1A2CYP2D6
SCHEMBL5560787 0.89 PTGS2 (0.49) PTGS2
SCHEMBL5824081 0.88 PTGS2 (0.50) AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL5553629 0.88 PTGS2 (0.49) AKR1C3AKR1C2PTGS2
SCHEMBL5440977 0.88 AKR1C3 (0.62) AKR1C3AKR1C2LMNACYP1A2CYP2D6
SCHEMBL5558845 0.88 PTGS2 (0.51) AKR1C3AKR1C2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010062221-A1 SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1N-INDOLE-3-IL) ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES АЛЛА XEM, ЛЛС (US) 2010-06-03 WO disclosed
US-20070161698-A1 Modulators of CRTH2 Activity MICROBIA, INC. 2007-07-12 US disclosed
US-7205329-B2 Modulators of CRTH2 activity MICROBIA, INC. (US) 2007-04-17 US disclosed
US-20060135591-A1 Modulators of CRTH2 activity IRONWOOD PHARMACEUTICALS, INC. 2006-06-22 US disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135591-A1 Modulators of CRTH2 activity HRH2, HRH1, MRGPRX2 AKR1C3 3064/4885AKR1C2 2503/4885LMNA 4458/4885
US-20070161698-A1 Modulators of CRTH2 Activity HRH2, HRH1, MRGPRX2 AKR1C3 3064/4885AKR1C2 2503/4885LMNA 4458/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885LMNA 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.